Journal of medical virology · 2021
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boshier Florencia A T, Pang Juanita, Penner Justin, Parker Matthew, Alders Nele, Bamford Alasdair, Grandjean Louis, Grunewald Stephanie, Hatcher James, Best Timothy, Dalton Caroline, Bynoe Patricia Dyal, Frauenfelder Claire, Köeglmeier Jutta, Myerson Phoebe, Roy Sunando, Williams Rachel, de Silva Thushan I, Goldstein Richard A, Breuer Judith, COVID-19 Genomics UK (COG-UK) consortium
Аннотация
Detailed information on intrahost viral evolution in SARS-CoV-2 with and without treatment is limited. Sequential viral loads and deep sequencing of SARS-CoV-2 from the upper respiratory tract of nine hospitalized children, three of whom were treated with remdesivir, revealed that remdesivir treatment suppressed viral load in one patient but not in a second infected with an identical strain without any evidence of drug resistance found. Reduced levels of subgenomic RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication. Haplotype reconstruction uncovered persistent SARS-CoV-2 variant genotypes in four patients. These likely arose from within-host evolution, although superinfection cannot be excluded in one case. Although our dataset is small, observed sample-to-sample heterogeneity in variant frequencies across four of nine patients suggests the presence of discrete viral populations in the lung with incomplete population sampling in diagnostic swabs. Such compartmentalization could compromise the penetration of remdesivir into the lung, limiting the drugs in vivo efficacy, as has been observed in other lung infections.